Quarterly report pursuant to Section 13 or 15(d)

Cash Equivalents and Marketable Securities

v3.19.2
Cash Equivalents and Marketable Securities
6 Months Ended
Jun. 30, 2019
Cash And Cash Equivalents [Abstract]  
Cash Equivalents and Marketable Securities

4. Cash Equivalents and Marketable Securities

Cash equivalents and marketable securities consisted of the following:

 

 

 

June 30, 2019

 

 

 

Amortized

Cost Basis

 

 

Unrealized

Gains

 

 

Fair

Value

 

 

 

(in thousands)

 

Money market funds

 

$

17,209

 

 

$

 

 

$

17,209

 

Commercial paper

 

 

38,810

 

 

 

 

 

 

38,810

 

Corporate debt securities

 

 

50,517

 

 

 

92

 

 

 

50,609

 

Asset-based securities

 

 

32,447

 

 

 

68

 

 

 

32,515

 

U.S. government agencies

 

 

26,850

 

 

 

52

 

 

 

26,902

 

Total

 

 

165,833

 

 

 

212

 

 

 

166,045

 

Less amounts classified as cash equivalents

 

 

(17,209

)

 

 

 

 

 

(17,209

)

Total marketable securities

 

$

148,624

 

 

$

212

 

 

$

148,836

 

 

 

 

December 31, 2018

 

 

 

Amortized

Cost Basis

 

 

Unrealized

Losses

 

 

Fair

Value

 

 

 

(in thousands)

 

Money market funds

 

$

116,202

 

 

$

 

 

$

116,202

 

Commercial paper

 

 

26,625

 

 

 

 

 

 

26,625

 

Corporate debt securities

 

 

11,795

 

 

 

(21

)

 

 

11,774

 

Asset-based securities

 

 

16,920

 

 

 

(21

)

 

 

16,899

 

U.S. government agencies

 

 

23,901

 

 

 

(5

)

 

 

23,896

 

Total

 

 

195,443

 

 

 

(47

)

 

 

195,396

 

Less amounts classified as cash equivalents

 

 

(116,202

)

 

 

 

 

 

(116,202

)

Total marketable securities

 

$

79,241

 

 

$

(47

)

 

$

79,194

 

 

As of June 30, 2019, $15.1 million of marketable securities had maturities of more than one year and are classified as long-term assets.  As of December 31, 2018, no marketable securities had maturities of more than one year.

There were $13.0 million and $52.6 million investments in an unrealized loss position as of June 30, 2019 and December 31, 2018, respectively. During the three and six months ended June 30, 2019 and 2018 we did not record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.